Publication date: Jul 24, 2024
We compared the cost-effectiveness of hospital-based treatment and that of community treatment centres (CTCs). We performed statistical analysis to compare the expenses incurred by COVID-19 patients who received hospital care with those incurred by COVID-19 patients who went to CTCs. A study was conducted on 411 530 COVID-19 inpatients and 243 329 CTC patients from January 2020 to December 2021. We calculated the probability of severe disease, hospitalisation period and medical expenses for inpatients and CTC patients. Subsequently, we analysed the cost-effectiveness of CTC compared with hospitalisation. Comparing medical expenses, CTC patients incurred 2 220 000 KRW on average, which is less than the expenses incurred by hospitalised COVID-19 patients. The study suggests that using a CTC may be more cost-effective than a hospital service alone.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | VO | effectiveness |
| disease | MESH | COVID-19 |
| disease | VO | effective |
| disease | MESH | Long Covid |
| disease | IDO | symptom |
| drug | DRUGBANK | Trestolone |
| disease | MESH | critically ill |
| disease | IDO | facility |
| drug | DRUGBANK | Coenzyme M |
| disease | VO | time |
| disease | VO | pregnant women |
| drug | DRUGBANK | Methionine |
| disease | MESH | obesity |
| disease | MESH | vaginal bleeding |
| disease | MESH | lung diseases |
| disease | MESH | asthma |
| pathway | KEGG | Asthma |
| disease | MESH | heart failure |
| drug | DRUGBANK | Oxygen |
| drug | DRUGBANK | Etoperidone |
| disease | MESH | pneumonia |
| disease | MESH | syndrome |
| disease | MESH | ‘death |
| disease | MESH | infection |
| disease | IDO | production |
| drug | DRUGBANK | Isoxaflutole |
| disease | VO | protocol |
| disease | VO | publication |
| pathway | REACTOME | Translation |
| disease | MESH | Emergency |
| disease | VO | Imovax ID |
| pathway | KEGG | Coronavirus disease |
| disease | MESH | reinfection |